Multiple Sclerosis Clinical Trial
— NorsemanOfficial title:
Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis: A Randomised Controlled Trial: The NORSEMAN Study
The purpose of this study is to assess the safety and efficacy of Nicotinamide riboside (NR) for treatment of patients with progressive multiple sclerosis. The main question it aims to answer is: • Does NR delay disability progression in progressive multiple sclerosis? Participants will be treated with NR or placebo for 30 months,
Status | Recruiting |
Enrollment | 300 |
Est. completion date | December 30, 2027 |
Est. primary completion date | August 1, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - A diagnosis of progressive MS (secondary; SPMS or primary; PPMS) according to the 2013 revisions of clinical course of multiple sclerosis and the 2017 revisions of the McDonald criteria. - Aged 18-65 years. - EDSS 3-6.5 - Able to perform T25FW test - The participant must have documented evidence of disability progression observed during the 24 months before screening. - With or without a stable disease modifying therapy during the last three months. - Written informed consent for study participation. Exclusion Criteria: - A diagnosis of relapsing MS according to the revisions of the McDonald criteria - Neoplastic disease at baseline - Previous history of malignant melanoma or breast cancer - Stable phase of a progressive disease course - Pregnancy or lactating female patients - Dementia or other neurodegenerative disorder at baseline visit - Comorbidity (psychiatric or somatic) that precludes study participation - Use of high dose vitamin B3 supplementation within 30 days of enrolment - Genetically confirmed mitochondrial disease or metabolic disorder |
Country | Name | City | State |
---|---|---|---|
Norway | Haukeland University Hospital | Bergen |
Lead Sponsor | Collaborator |
---|---|
Haukeland University Hospital |
Norway,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of patients with sustained disability progression over the treatment period | Defined as an increase in either expanded disability status scale (EDSS), timed 25 foot -walk test (T25W) or 9-hole-peg test.
EDSS is measured in scores from 0 - 10. The higher the score the less ambulatory ability. Progression is defined as an increase of >/=1.0 point if baseline EDSS is = 5.5 or an increase of >/=0.5 point if baseline EDSS is >/= 5.5. Progression in T25WT and 9HPT is defined as an increase of 20% from baseline measures in minutes/seconds. |
Baseline to month 30 | |
Secondary | To determine the efficacy of NR compared with placebo, as reflected by EDSS | Proportion of patients with sustained disability progression over the treatment period | Baseline to month 30 | |
Secondary | To determine the efficacy of NR compared with placebo, as reflected by 25-footwalk | Proportion of patients with sustained disability progression over the treatment period | Baseline to month 30 | |
Secondary | To determine the efficacy of NR compared with placebo, as reflected by 9-Hole Peg test | Proportion of patients with sustained disability progression over the treatment period | Baseline to month 30 | |
Secondary | To determine the efficacy of NR compared with placebo, as reflected by total volume of T2 lesions on MRI scans of the brain | MRI | Baseline to month 24 | |
Secondary | To determine the efficacy of NR compared with placebo, as reflected by formation of lesions | MRI | Baseline to month 24 | |
Secondary | Changes in brain atrophy in NR-treated patients with primary progressive multiple sclerosis as compared with placebo | MRI | Baseline to month 24 | |
Secondary | Time to onset of sustained disability progression over the treatment period | Increase in either EDSS, T25FW or 9HPT that is sustained for at least 6 months | Baseline to month 30 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT02845635 -
MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis
|